D-1249-2019 Class II Ongoing
FDA drug recall D-1249-2019 was initiated by AVKARE Inc. on Apr 24, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million. The recall status is ongoing. Affected quantity: 1438 cartons (71,900 tablets).
Recall details
- Product Type
- Drugs
- Report Date
- May 8, 2019
- Initiation Date
- Apr 24, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1438 cartons (71,900 tablets)
Product description
Losartan Potassium Tablets USP 50 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-517-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478
Reason for recall
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
Distribution pattern
Nationwide
Code information
Lot: 20121 Exp. 6/30/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1249-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026